Q3 2025 Bio-Techne Corp Earnings Call Transcript
Key Points
- Bio-Techne Corp (TECH) reported a strong quarter with 6% organic revenue growth despite a challenging macro environment.
- The company achieved an adjusted operating margin of 34.9%, highlighting operational efficiencies and profitability.
- Bio-Techne's protein sciences segment saw 7% organic revenue growth, driven by strong demand for proteomic reagents and cell therapy workflow solutions.
- The diagnostics and spatial biology segment delivered 2% organic revenue growth, with notable progress in the ExoDx prostate cancer test and spatial biology instruments.
- Bio-Techne is well-positioned to benefit from potential shifts in NIH funding towards research areas like cancer and neurological disorders, aligning with their product portfolio.
- Uncertainty around NIH funding and US policy shifts is causing concern among US academic customers, potentially impacting future research project funding.
- The recent escalation of global tariffs poses a challenge, with a potential $20 million annual impact on adjusted operating income if not mitigated.
- China's economic situation remains challenging, with mid-single-digit revenue declines in the region.
- The academic market in the US is facing headwinds due to NIH funding uncertainties, impacting purchase decisions, particularly for capital equipment.
- Bio-Techne anticipates a temporary slowdown in growth momentum to low single digits in Q4 due to macro uncertainties, including tariffs and potential NIH budget cuts.
Good morning and welcome to Bio-Techne earnings conference call for the third quarter of fiscal year 2025. At this time, all participants have been placed in listen-only mode and the call will be open for questions following the management's prepared remarks.
During a Q&A session, please limit yourself to one question and a follow-up. I would now like to turn the call over to David Clair, Bio-Techne's Vice President, Investor Relations. Please go ahead.
Good morning and thank you for joining us. On the call with me this morning are Kim Kelderman, President and Chief Executive Officer, and Jim Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our Safe Harbor statement.
Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company's future results. The company's 10-K for fiscal year 2024 identifies certain factors that could cause the company's actual results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
